Ifng-Venus-Luc

Fig1.MC38-OVA tumor volumes in Ifng-Venus-Luci reporter mice treated or not with anti-PD-1 mAb. Arrows indicate treatment days.

Fig2. In vivo imaging validation of  MC38-OVA  tumors in Ifng-Venus-Luci reporter mice treated or not with anti-PD-1 mAb.

In PBS treated control tumor, the IFNγ signal increased as the tumor growing. In anti-PD1 treated tumor, increased average BLI (Bioluminescent imaging) of IFNγ was shown 48h post the first dose compared to control group;  as the tumor regression upon PD1 treatment, the IFNγ signal in tumor decreased as well.

The data is provided by Crownbio.